To make headroom for expensive, potentially curative therapies in the pipeline, the healthcare needs to remove ineffective care from the system, said Susan Dentzer, visiting fellow at the Duke-Margolis Center for Health Policy.
To make headroom for expensive, potentially curative therapies in the pipeline, the healthcare needs to remove ineffective care from the system, said Susan Dentzer, visiting fellow at the Duke-Margolis Center for Health Policy.
Transcript
How do we balance the desire for innovation with the rising costs of healthcare delivery, particularly in cancer care?
We balance it awkwardly to be frank. We have at least a thousand innovative cancer drugs in the pipeline today, which will be coming to the market over the next several years. Many of them will be life-changing therapies. They will essentially, but not necessarily, be cures, but they really will be disease-modifying therapies. People are going to want them. And we’re going to want to integrate them into our health system.
The issue, I think, on balance is how much of care that we are currently undertaking that is not all that effective can we displace? Therefore, if we bring on board therapies that are even more effective, are we at least achieving higher value even if the costs go up? That, alone, would be a positive. But, let’s face it: We have all kinds of forces that are going to drive us to higher and higher rates of healthcare spending and what is going to happen in cancer, I’m sure, is one of them.
With Hidradenitis Suppurativa, Maternal and Offspring Outcomes May Suffer
October 31st 2024Novel evidence has emerged from a 16-year study that hidradenitis suppurativa can elevate risks of not only pregnancy and postpartum complications, but of morbidity—particularly metabolic- and immunology-related morbidity—for mother and child in the long term.
Read More
Building Trust, Breaking Barriers: Health Care Leaders Tackle Primary Care Challenges
August 8th 2024On this episode of Managed Care Cast, we're talking with the chief medical officers of CVS Health and Aetna, as well as CVS Health's chief health equity officer, about primary and preventive care engagement, the impact of telehealth, and the role of trust in patient-provider relationships.
Listen
Low Pulmonary Rehabilitation, Palliative Care Referrals for Patients With IPF Persist
October 30th 2024Despite proven benefits, referrals to pulmonary rehabilitation and palliative care for patients with idiopathic pulmonary fibrosis (IPF) in England remain significantly lower than for other respiratory conditions.
Read More
New AI Tool Identifies Undiagnosed PNH in Health Records
October 30th 2024The machine learning model shows promise in detecting paroxysmal nocturnal hemoglobinuria (PNH) by assessing electronic health records (EHR) data, potentially transforming the diagnostic landscape for rare diseases.
Read More